PIK3CA mutations in small bowel adenocarcinoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• PIK3CA mutations are frequent in various cancers.
• PIK3CA mutations are rarely reported in small bowel adenocarcinoma (SBA).
• PIK3CA pathway inhibitors show promise for targeted therapy.

Observation:

• A case of sporadic jejunal cancer with an exon 9 PIK3CA mutation (E542K) is presented.
• A literature and database search identified additional cases of PIK3CA mutations in SBA.
• The study analyzed PIK3CA mutation status in 86 SBA samples.

Findings:

• PIK3CA mutations were identified in 9.3% of SBA samples (8 out of 86).
• Mutations were more prevalent in the duodenum (62.5%) and commonly located in exon 9.
• The overall significance of PIK3CA mutations in SBA remains to be elucidated.

Implications:

• PIK3CA mutations may represent a therapeutic target in a subset of SBA patients.
• Larger cohort studies are necessary to correlate PIK3CA mutations with clinical and pathological variables.
• Further investigation is warranted to understand the role of PIK3CA mutations in SBA progression and survival.